Immunotherapy Drugs Market by Type, by Therapy Area, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023

Immunotherapy drugs market is forecasted to attain a size of $227.6 billion by 2023, with the thriving demand and increase in the development of monoclonal antibodies (mAbs), increasing prevalence of chronic diseases, and growing implementation of target therapy, the market is expected to progress significantly in the coming years.

Based on type, the immunotherapy drugs market has been categorized into checkpoint inhibitors and vaccines. Among these two, the checkpoint inhibitors category generated higher revenue in the historical period, and is expected to generate more than $100.0 billion revenue by 2023. Increasing development of mAbs, and rise in the adoption of chimeric antigen receptor (CAR) T-cell therapy are the major factors contributing to the larger share of this category.

Vaccines are further sub-categorized on the basis of type and brand. The two types of vaccines available in the immunotherapy drugs market are preventive and therapeutic vaccines. Among these, preventive vaccines held a larger share in the market. Among the various brand of vaccines available, Prevnar/Prevenar 13 is one of the bestseller vaccines brands and generated the highest revenue of $5.6 billion in the market, in 2017.

Immunotherapy drugs are majorly used for the treatment of cancer, autoimmune and inflammatory diseases, and infectious diseases. Cancer held the largest share in the immunotherapy drugs market for therapy area, in 2017. This can be ascribed to the increasing prevalence of cancer across the globe.

On the basis of end user, the immunotherapy drugs market has been categorized into hospitals and clinics, and individuals. Of these, hospitals and clinics are expected to demonstrate faster growth, at a CAGR of 14.0% during the forecast period. This can be attributed to the increasing patient base in hospitals and clinics, which leads to high requirement of immunotherapy drugs in this end-user category.

The APAC immunotherapy drugs market is expected to observe the fastest growth, at a CAGR of 14.3% during the forecast period, mainly on account of increasing healthcare expenditure for the improvement of healthcare infrastructure and growing research and development (R&D) activities in the region.

The players in the immunotherapy drugs industry are enhancing their product portfolio through product launches and also have received approvals from government organizations for its application. For instance, in September 2018, Sanofi received approval for Libyato for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC, who are not candidates for curative surgery or curative radiation.

Likewise, in September 2018, AstraZeneca plc received the U.S. Food and Drug Administration (USFDA) approval for Lumoxiti (moxetumomab pasudotox-tdfk). AstraZeneca plc developed Lumoxiti together with MedImmune LLC, for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (HCL), who have received at least two prior systemic therapies, including purine nucleoside analog treatment.

F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Novartis International AG, Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Medigene AG, C. H. Boehringer Sohn AG & Co. KG, Takeda Pharmaceutical Company Limited, Celgene Corporation, and Pfizer Inc. are other key players present in the immunotherapy drugs market.

The scope of study also includes the epidemiology coverage for cancer, autoimmune and inflammatory diseases, and infectious diseases; pricing and reimbursement scenario for immunotherapy drugs; research and funding initiatives for immunotherapy drugs; and list of immunotherapy drugs in the pipeline of the key market players.

Chapter 1. Research Background

1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Type
1.3.2 Market Segmentation by Therapy Area
1.3.3 Market Segmentation by End User
1.3.4 Market Segmentation by Geography
1.3.5 Analysis Period
1.3.6 Market Data Reporting Unit
1.3.6.1 Value
1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By region
2.2.1.2 By industry participant
2.2.1.3 By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Industry Insights

4.1 Epidemiology Analysis
4.1.1 Cancer
4.1.2 Autoimmune and Inflammatory Diseases
4.1.2.1 Autoimmune diseases
4.1.2.2 Inflammatory diseases
4.1.3 Infectious Diseases
4.2 Pricing and Reimbursement Scenario for Immunotherapy Drugs
4.2.1 Global
4.2.2 Europe
4.2.2.1 U.K.
4.2.2.2 Belgium
4.2.2.3 France
4.2.2.4 Italy
4.2.2.5 Spain
4.2.3 North America
4.2.3.1 U.S.
4.2.4 APAC
4.2.4.1 Japan
4.2.4.2 China
4.2.4.3 Australia
4.3 Research and Funding Initiatives for Immunotherapy Drugs
4.4 List of Pipeline Drugs
4.4.1 Sanofi
4.4.2 Pfizer Inc.
4.4.3 Novartis AG
4.4.4 Merck & Co. Inc.
4.4.5 Johnson & Johnson
4.4.6 GlaxoSmithKline plc
4.4.7 F. Hoffman-La Roche Ltd.
4.4.8 Eli Lilly and Company
4.4.9 Celgene Corporation
4.4.10 C. H. Boehringer Sohn AG & Co. KG
4.4.11 Bristol-Myers Squibb Company
4.4.12 AstraZeneca PLC
4.4.13 AbbVie Inc.
4.5 Treatment Protocols and Line of Therapies
4.5.1 First-Line Therapy for Treating Cancer
4.5.2 Second-Line Therapy for Treating Cancer
4.5.3 Other Treatments
4.5.3.1 Targeted therapy
4.5.3.2 Hormone therapy

Chapter 5. Introduction

5.1 Definition of Market Segments
5.1.1 By Type
5.1.1.1 Checkpoint inhibitors
5.1.1.1.1 By brand
5.1.1.1.1.1 Humira
5.1.1.1.1.2 Rituxan/MabThera
5.1.1.1.1.3 Herceptin
5.1.1.1.1.4 Remicade
5.1.1.1.1.5 Enbrel
5.1.1.1.1.6 Others
5.1.1.2 Vaccines
5.1.1.2.1 By type
5.1.1.2.1.1 Preventive vaccines
5.1.1.2.1.2 Therapeutic vaccines
5.1.1.2.2 By brand
5.1.1.2.2.1 Prevnar/ Prevenar 13
5.1.1.2.2.2 Gardasil
5.1.1.2.2.3 ProQuad
5.1.1.2.2.4 Rotarix
5.1.1.2.2.5 Others
5.1.2 By Therapy Area
5.1.2.1 Cancer
5.1.2.2 Autoimmune and inflammatory diseases
5.1.2.3 Infectious diseases
5.1.3 By End User
5.1.3.1 Hospitals and clinics
5.1.3.2 Individuals
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Surge in the prevalence of chronic diseases
5.2.1.2 Thriving demand and development of mAbs
5.2.1.3 Rise in the implementation of target therapy
5.2.1.4 Increasing availability of biosimilars
5.2.1.5 Impact analysis of drivers on market forecast
5.2.2 Restraints
5.2.2.1 High cost of immunotherapy treatment
5.2.2.2 Impact analysis of restraints on market forecast
5.3 Porter’s Five Forces Analysis

Chapter 6. Global Market Size and Forecast

6.1 By Type
6.1.1 Checkpoint Inhibitors Market, by Brand
6.1.2 Vaccines Market, by Type
6.1.3 Vaccines Market, by Brand
6.2 By Therapy Area
6.3 By End User
6.4 By Region

Chapter 7. North America Market Size and Forecast

7.1 By Therapy Area
7.2 By End User
7.3 By Country

Chapter 8. Europe Market Size and Forecast

8.1 By Therapy Area
8.2 By End User
8.3 By Country

Chapter 9. APAC Market Size and Forecast

9.1 By Therapy Area
9.2 By End User
9.3 By Country

Chapter 10. LATAM Market Size and Forecast

10.1 By Therapy Area
10.2 By End User
10.3 By Country

Chapter 11. MEA Market Size and Forecast

11.1 By Therapy Area
11.2 By End User
11.3 By Country

Chapter 12. Competitive Landscape

12.1 Product Benchmarking of Key Players
12.2 Global Strategic Developments of Key Players
12.2.1 Mergers and Acquisitions
12.2.2 Product Launches and Approvals
12.2.3 Collaborations, Partnerships and Agreements
12.2.4 Other Developments

Chapter 13. Company Profiles

13.1 Eli Lilly and Company
13.1.1 Business Overview
13.1.2 Product and Service Offerings
13.1.2.1 Marketed products
13.1.2.2 Pipeline products
13.1.3 Key Financial Summary
13.2 Sanofi
13.2.1 Business Overview
13.2.2 Product and Service Offerings
13.2.2.1 Marketed products
13.2.2.2 Pipeline products
13.2.3 Key Financial Summary
13.3 Novartis AG
13.3.1 Business Overview
13.3.2 Product and Service Offerings
13.3.2.1 Marketed products
13.3.2.2 Pipeline products
13.3.3 Key Financial Summary
13.4 AbbVie Inc.
13.4.1 Business Overview
13.4.2 Product and Service Offerings
13.4.2.1 Marketed products
13.4.2.2 Pipeline products
13.4.3 Key Financial Summary
13.5 F. Hoffmann-La Roche Ltd.
13.5.1 Business Overview
13.5.2 Product and Service Offerings
13.5.2.1 Marketed products
13.5.2.2 Pipeline products
13.5.3 Key Financial Summary
13.6 AstraZeneca PLC
13.6.1 Business Overview
13.6.2 Product and Service Offerings
13.6.2.1 Marketed products
13.6.2.2 Pipeline products
13.6.3 Key Financial Summary
13.7 Merck & Co. Inc.
13.7.1 Business Overview
13.7.2 Product and Service Offerings
13.7.2.1 Marketed products
13.7.2.2 Pipeline products
13.7.3 Key Financial Summary
13.8 GlaxoSmithKline plc
13.8.1 Business Overview
13.8.2 Product and Service Offerings
13.8.2.1 Marketed products
13.8.2.2 Pipeline products
13.8.3 Key Financial Summary
13.9 Bristol-Myers Squibb Company
13.9.1 Business Overview
13.9.2 Product and Service Offerings
13.9.2.1 Marketed products
13.9.2.2 Pipeline products
13.9.3 Key Financial Summary
13.10 Amgen Inc.
13.10.1 Business Overview
13.10.2 Product and Service Offerings
13.10.2.1 Marketed products
13.10.2.2 Pipeline products
13.10.3 Key Financial Summary
13.11 C. H. Boehringer Sohn AG & Co. KG
13.11.1 Business Overview
13.11.2 Product and Service Offerings
13.11.2.1 Marketed products
13.11.2.2 Pipeline products
13.11.3 Key Financial Summary
13.12 Celgene Corporation
13.12.1 Business Overview
13.12.2 Product and Service Offerings
13.12.2.1 Marketed products
13.12.2.2 Pipeline products
13.12.3 Key Financial Summary
13.13 Johnson & Johnson
13.13.1 Business Overview
13.13.2 Product and Service Offerings
13.13.2.1 Marketed products
13.13.2.2 Pipeline products
13.13.3 Key Financial Summary
13.14 Takeda Pharmaceutical Company Limited
13.14.1 Business Overview
13.14.2 Product and Service Offerings
13.14.2.1 Marketed products
13.14.2.2 Pipeline products
13.14.3 Key Financial Summary
13.15 Pfizer Inc.
13.15.1 Business Overview
13.15.2 Product and Service Offerings
13.15.2.1 Marketed products
13.15.2.2 Pipeline products:
13.15.3 Key Financial Summary

Chapter 14. Appendix

14.1 Abbreviations
14.2 Sources and References
14.3 Related Reports

List of Tables

TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 IMMUNOTHERAPY PIPELINE DRUGS BY SANOFI
TABLE 3 IMMUNOTHERAPY PIPELINE DRUGS BY PFIZER INC.
TABLE 4 IMMUNOTHERAPY PIPELINE DRUGS BY NOVARTIS AG
TABLE 5 IMMUNOTHERAPY PIPELINE DRUGS BY MERCK & CO. INC.
TABLE 6 IMMUNOTHERAPY PIPELINE DRUGS BY JOHNSON & JOHNSON
TABLE 7 IMMUNOTHERAPY PIPELINE DRUGS BY GLAXOSMITHKLINE PLC
TABLE 8 IMMUNOTHERAPY PIPELINE DRUGS BY F. HOFFMAN-LA ROCHE LTD.
TABLE 9 IMMUNOTHERAPY PIPELINE DRUGS BY ELI LILLY AND COMPANY
TABLE 10 IMMUNOTHERAPY PIPELINE DRUGS BY CELGENE CORPORATION
TABLE 11 IMMUNOTHERAPY PIPELINE DRUGS BY C. H. BOEHRINGER SOHN AG & CO. KG
TABLE 12 IMMUNOTHERAPY PIPELINE DRUGS BY BRISTOL-MYERS SQUIBB COMPANY
TABLE 13 IMMUNOTHERAPY PIPELINE DRUGS BY ASTRAZENECA PLC
TABLE 14 IMMUNOTHERAPY PIPELINE DRUGS BY ABBVIE INC.
TABLE 15 SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE CANCER (MELANOMA)
TABLE 16 INTRAVENOUS IMMUNE GLOBULIN PRODUCTS LICENSED BY USFDA FOR THE TREATMENT OF INFECTIOUS DISEASES
TABLE 17 IMMUNOTHERAPEUTIC AGENTS UNDER CLINICAL STAGES FOR THE TREATMENT OF INFECTIOUS DISEASES
TABLE 18 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2013-2017)
TABLE 19 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2018-2023)
TABLE 20 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2013-2017)
TABLE 21 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2018-2023)
TABLE 22 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2013-2017)
TABLE 23 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2018-2023)
TABLE 24 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2013-2017)
TABLE 25 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2018-2023)
TABLE 26 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
TABLE 27 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
TABLE 28 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
TABLE 29 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
TABLE 30 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $B (2013-2017)
TABLE 31 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY REGION, $B (2018-2023)
TABLE 32 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
TABLE 33 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
TABLE 34 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
TABLE 35 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
TABLE 36 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
TABLE 37 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
TABLE 38 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
TABLE 39 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
TABLE 40 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
TABLE 41 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
TABLE 42 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
TABLE 43 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
TABLE 44 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
TABLE 45 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
TABLE 46 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
TABLE 47 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
TABLE 48 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
TABLE 49 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
TABLE 50 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
TABLE 51 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
TABLE 52 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
TABLE 53 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
TABLE 54 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
TABLE 55 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
TABLE 56 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2017)
TABLE 57 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2018-2023)
TABLE 58 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2017)
TABLE 59 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2018-2023)
TABLE 60 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2017)
TABLE 61 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2018-2023)
TABLE 62 ELI LILLY AND COMPANY - AT A GLANCE
TABLE 63 ELI LILLY AND COMPANY - KEY FINANCIAL SUMMARY
TABLE 64 SANOFI - AT A GLANCE
TABLE 65 SANOFI - KEY FINANCIAL SUMMARY
TABLE 66 NOVARTIS AG - AT A GLANCE
TABLE 67 NOVARTIS AG - KEY FINANCIAL SUMMARY
TABLE 68 ABBVIE INC. - AT A GLANCE
TABLE 69 ABBVIE INC. - KEY FINANCIAL SUMMARY
TABLE 70 F. HOFFMANN-LA ROCHE LTD. - AT A GLANCE
TABLE 71 F. HOFFMANN-LA ROCHE LTD. - KEY FINANCIAL SUMMARY
TABLE 72 ASTRAZENECA PLC - AT A GLANCE
TABLE 73 ASTRAZENECA PLC - KEY FINANCIAL SUMMARY
TABLE 74 MERCK & CO. INC. - AT A GLANCE
TABLE 75 MERCK & CO. INC. - KEY FINANCIAL SUMMARY
TABLE 76 GLAXOSMITHKLINE PLC - AT A GLANCE
TABLE 77 GLAXOSMITHKLINE PLC - KEY FINANCIAL SUMMARY
TABLE 78 BRISTOL-MYERS SQUIBB COMPANY - AT A GLANCE
TABLE 79 BRISTOL-MYERS SQUIBB COMPANY - KEY FINANCIAL SUMMARY
TABLE 80 AMGEN INC. - AT A GLANCE
TABLE 81 AMGEN INC. - KEY FINANCIAL SUMMARY
TABLE 82 C. H. BOEHRINGER SOHN AG & CO. KG - AT A GLANCE
TABLE 83 C. H. BOEHRINGER SOHN AG & CO. KG - KEY FINANCIAL SUMMARY
TABLE 84 CELGENE CORPORATION - AT A GLANCE
TABLE 85 CELGENE CORPORATION - KEY FINANCIAL SUMMARY
TABLE 86 JOHNSON & JOHNSON - AT A GLANCE
TABLE 87 JOHNSON & JOHNSON - KEY FINANCIAL SUMMARY
TABLE 88 TAKEDA PHARMACEUTICAL COMPANY LIMITED - AT A GLANCE
TABLE 89 TAKEDA PHARMACEUTICAL COMPANY LIMITED - KEY FINANCIAL SUMMARY
TABLE 90 PFIZER INC. - AT A GLANCE
TABLE 91 PFIZER INC. - KEY FINANCIAL SUMMARY

List of Figures

FIG 1 RESEARCH SCOPE
FIG 2 RESEARCH METHODOLOGY
FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION
FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
FIG 7 DATA TRIANGULATION APPROACH
FIG 8 GLOBAL IMMUNOTHERAPY DRUGS MARKET SUMMARY
FIG 9 PREVALENCE OF MULTIPLE SCLEROSIS PER 100,000 PEOPLE IN EUROPEAN COUNTRIES (2015)
FIG 10 REIMBURSEMENT STATUS OF CANCER MEDICINES LAUNCHED DURING 2011-2015, IN SOME MAJOR COUNTRIES
FIG 11 IMPACT ANALYSIS OF DRIVERS ON MARKET FORECAST
FIG 12 IMPACT ANALYSIS OF DRIVERS ON MARKET FORECAST
FIG 13 BARGAINING POWER OF BUYERS
FIG 14 BARGAINING POWER OF SUPPLIERS
FIG 15 INTENSITY OF RIVALRY
FIG 16 THREAT OF NEW ENTRANTS
FIG 17 THREAT OF SUBSTITUTES
FIG 18 SNAPSHOT OF GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, (2017)
FIG 19 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY TYPE, $B (2013-2023)
FIG 20 GLOBAL IMMUNOTHERAPY CHECKPOINT INHIBITORS MARKET, BY BRAND, $B (2013-2023)
FIG 21 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY TYPE, $B (2013-2023)
FIG 22 GLOBAL IMMUNOTHERAPY VACCINES MARKET, BY BRAND, $B (2013-2023)
FIG 23 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
FIG 24 GLOBAL IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
FIG 25 WORLDWIDE MAJOR MARKETS FOR IMMUNOTHERAPY DRUGS
FIG 26 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIG 27 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
FIG 28 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
FIG 29 NORTH AMERICA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
FIG 30 EUROPE IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIG 31 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
FIG 32 HEALTHCARE DATA FOR SPAIN, DENMARK AND AUSTRIA (FOR THE YEARS 2000, 2008 & 2015)
FIG 33 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
FIG 34 EUROPE IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
FIG 35 APAC IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIG 36 APAC IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
FIG 37 APAC IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
FIG 38 APAC IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
FIG 39 LATAM IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIG 40 LATAM IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
FIG 41 LATAM IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
FIG 42 LATAM IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
FIG 43 MEA IMMUNOTHERAPY DRUGS MARKET SNAPSHOT
FIG 44 MEA IMMUNOTHERAPY DRUGS MARKET, BY THERAPY AREA, $B (2013-2023)
FIG 45 MEA IMMUNOTHERAPY DRUGS MARKET, BY END USER, $B (2013-2023)
FIG 46 MEA IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, $B (2013-2023)
FIG 47 PRODUCT BENCHMARKING OF KEY PLAYERS
FIG 48 ELI LILLY AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 49 SANOFI - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 50 NOVARTIS AG - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2017)
FIG 51 ABBVIE INC. - REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)
FIG 52 F. HOFFMANN-LA ROCHE LTD. - REVENUE SPLIT BY DIVISION AND GEOGRAPHY (2017)
FIG 53 ASTRAZENECA PLC - REVENUE SPLIT BY THERAPY AREA AND GEOGRAPHY (2017)
FIG 54 MERCK & CO. INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 55 GLAXOSMITHKLINE PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 56 BRISTOL-MYERS SQUIBB COMPANY - REVENUE SPLIT BY PRODUCT CATEGORY AND GEOGRAPHY (2017)
FIG 57 AMGEN INC. - REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)
FIG 58 C. H. BOEHRINGER SOHN AG & CO. KG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 59 CELGENE CORPORATION - REVENUE SPLIT BY PRODUCT SALES AND GEOGRAPHY (2017)
FIG 60 JOHNSON & JOHNSON - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 61 TAKEDA PHARMACEUTICAL COMPANY LIMITED - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2016)
FIG 62 PFIZER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)